{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:12:14Z","timestamp":1781889134567,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070153"],"award-info":[{"award-number":["82070153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22331-5","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:03:59Z","timestamp":1762160639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Decreased expression of BCL2 protein on the diagnostic bone marrow T cells in adult acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Zong-Yan","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-Hong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Zhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"22331_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo, C. D., Erba, H. P., Freeman, S. D. & Wei, A. H. Acute myeloid leukaemia. Lancet 401, 2073\u20132086. https:\/\/doi.org\/10.1016\/s0140-6736(23)00108-3 (2023).","journal-title":"Lancet"},{"issue":"6","key":"22331_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3390\/cancers13061423","volume":"13","author":"S Sendker","year":"2021","unstructured":"Sendker, S., Reinhardt, D. & Niktoreh, N. Redirecting the Immune Microenvironment in Acute Myeloid Leukemia. Cancers (Basel) 13(6), 1423 (2021).","journal-title":"Cancers (Basel)"},{"key":"22331_CR3","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1038\/s41388-020-1239-y","volume":"39","author":"Z Li","year":"2020","unstructured":"Li, Z., Philip, M. & Ferrell, P. B. Alterations of T-cell-mediated immunity in acute myeloid leukemia. Oncogene 39, 3611\u20133619. https:\/\/doi.org\/10.1038\/s41388-020-1239-y (2020).","journal-title":"Oncogene"},{"key":"22331_CR4","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams, P. et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125, 1470\u20131481. https:\/\/doi.org\/10.1002\/cncr.31896 (2019).","journal-title":"Cancer"},{"key":"22331_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492\u2013499. https:\/\/doi.org\/10.1038\/ni.2035 (2011).","journal-title":"Nat. Immunol."},{"key":"22331_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00262-021-02978-5","volume":"71","author":"G Liu","year":"2022","unstructured":"Liu, G. et al. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis. Cancer Immunol. Immunother. 71, 277\u2013287. https:\/\/doi.org\/10.1007\/s00262-021-02978-5 (2022).","journal-title":"Cancer Immunol. Immunother"},{"key":"22331_CR7","doi-asserted-by":"crossref","unstructured":"Hafezi, S. & Rahmani, M. BCL-2 in Cancer: advances, challenges, and perspectives. Cancers (Basel) 13(6), 1292 (2021).","DOI":"10.3390\/cancers13061292"},{"key":"22331_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle, R. J. & Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47\u201359. https:\/\/doi.org\/10.1038\/nrm2308 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"22331_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer. 2, 647\u2013656. https:\/\/doi.org\/10.1038\/nrc883 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"22331_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/348334a0","volume":"348","author":"D Hockenbery","year":"1990","unstructured":"Hockenbery, D., Nu\u00f1ez, G., Milliman, C., Schreiber, R. D. & Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348, 334\u2013336 (1990).","journal-title":"Nature"},{"key":"22331_CR11","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1126\/science.3929382","volume":"229","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E. & Croce, C. M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229, 1390\u20131393 (1985).","journal-title":"Science"},{"key":"22331_CR12","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1093\/nar\/gkr223","volume":"39","author":"M Nambiar","year":"2011","unstructured":"Nambiar, M. & Raghavan, S. C. How does DNA break during chromosomal translocations? Nucleic Acids Res. 39, 5813\u20135825. https:\/\/doi.org\/10.1093\/nar\/gkr223 (2011).","journal-title":"Nucleic Acids Res."},{"key":"22331_CR13","first-page":"1191","volume":"145","author":"H Joensuu","year":"1994","unstructured":"Joensuu, H., Pylkk\u00e4nen, L. & Toikkanen, S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 145, 1191\u20131198 (1994).","journal-title":"Am. J. Pathol."},{"key":"22331_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1471-2407-10-186","volume":"10","author":"VK Anagnostou","year":"2010","unstructured":"Anagnostou, V. K. et al. High expression of BCL-2 predicts favorable outcome in Non-small cell lung cancer patients with Non squamous histology. BMC Cancer. 10, 186. https:\/\/doi.org\/10.1186\/1471-2407-10-186 (2010).","journal-title":"BMC Cancer"},{"key":"22331_CR15","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1038\/sj\/onc\/1205327","volume":"21","author":"S Kitada","year":"2002","unstructured":"Kitada, S., Pedersen, I. M., Schimmer, A. D. & Reed, J. C. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21, 3459\u20133474. https:\/\/doi.org\/10.1038\/sj\/onc\/1205327 (2002).","journal-title":"Oncogene"},{"key":"22331_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou, E. D. et al. BCL-2 Inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell. Stem Cell. 12, 329\u2013341. https:\/\/doi.org\/10.1016\/j.stem.2012.12.013 (2013).","journal-title":"Cell. Stem Cell."},{"key":"22331_CR17","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas, B. A. & Pollyea, D. A. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33, 2795\u20132804. https:\/\/doi.org\/10.1038\/s41375-019-0612-8 (2019).","journal-title":"Leukemia"},{"key":"22331_CR18","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos, L. et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81, 3091\u20133096. https:\/\/doi.org\/10.1182\/blood.V81.11.3091.3091 (1993).","journal-title":"Blood"},{"key":"22331_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1023\/A:1008255511404","volume":"9","author":"T Karakas","year":"1998","unstructured":"Karakas, T. et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 9, 159\u2013165 (1998).","journal-title":"Ann. Oncol."},{"key":"22331_CR20","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek, A. et al. Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to Azacitidine\/Venetoclax. Cancer Discov. 13, 1408\u20131427. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0939 (2023).","journal-title":"Cancer Discov"},{"key":"22331_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1386517","author":"G Corradi","year":"2024","unstructured":"Corradi, G. et al. Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1\u2009+\u2009TIM3\u2009+\u2009exhausted CD8\u2009+\u2009T cells. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1386517 (2024).","journal-title":"Front. Immunol."},{"key":"22331_CR22","doi-asserted-by":"publisher","unstructured":"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL). Zhonghua Xue Ye Xue Za Zhi 44, 705\u2013712 (2023). (2023). https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.09.001","DOI":"10.3760\/cma.j.issn.0253-2727.2023.09.001"},{"key":"22331_CR23","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett. 605, 217264. https:\/\/doi.org\/10.1016\/j.canlet.2024.217264 (2024).","journal-title":"Cancer Lett."},{"key":"22331_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-019-0841-1","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia. Diagn. Pathol. https:\/\/doi.org\/10.1186\/s13000-019-0841-1 (2019).","journal-title":"Diagn. Pathol."},{"key":"22331_CR25","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/sj.leu.2400854","volume":"11","author":"F Lauria","year":"1997","unstructured":"Lauria, F. et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 11, 2075\u20132078 (1997).","journal-title":"Leukemia"},{"key":"22331_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12943-022-01516-w","volume":"21","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion. Mol. Cancer. 21, 59. https:\/\/doi.org\/10.1186\/s12943-022-01516-w (2022).","journal-title":"Mol. Cancer"},{"key":"22331_CR27","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1084\/jem.20070618","volume":"204","author":"S Wojciechowski","year":"2007","unstructured":"Wojciechowski, S. et al. Bim\/Bcl-2 balance is critical for maintaining Naive and memory T cell homeostasis. J. Exp. Med. 204, 1665\u20131675. https:\/\/doi.org\/10.1084\/jem.20070618 (2007).","journal-title":"J. Exp. Med."},{"key":"22331_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.Cd-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp, F. J. et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint Blockade. Cancer Discov. 11, 68\u201379. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-0759 (2021).","journal-title":"Cancer Discov."},{"key":"22331_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/cdd.2017.30","volume":"24","author":"EM Carrington","year":"2017","unstructured":"Carrington, E. M. et al. Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell. Death Differ. 24, 878\u2013888. https:\/\/doi.org\/10.1038\/cdd.2017.30 (2017).","journal-title":"Cell. Death Differ."},{"key":"22331_CR30","first-page":"1191","volume":"9","author":"A Porwit-MacDonald","year":"1995","unstructured":"Porwit-MacDonald, A. et al. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 9, 1191\u20131198 (1995).","journal-title":"Leukemia"},{"key":"22331_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2141.1994.tb04984.x","volume":"88","author":"ZT Maung","year":"1994","unstructured":"Maung, Z. T. et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br. J. Haematol. 88, 105\u2013109. https:\/\/doi.org\/10.1111\/j.1365-2141.1994.tb04984.x (1994).","journal-title":"Br. J. Haematol."},{"key":"22331_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1023\/a:1008255511404","volume":"9","author":"T Karakas","year":"1998","unstructured":"Karakas, T. et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 9, 159\u2013165. https:\/\/doi.org\/10.1023\/a:1008255511404 (1998).","journal-title":"Ann. Oncol."},{"key":"22331_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","volume":"29","author":"J Tan","year":"2017","unstructured":"Tan, J. et al. Higher PD-1 expression concurrent with exhausted CD8\u2009+\u2009T cells in patients with de Novo acute myeloid leukemia. Chin. J. Cancer Res. 29, 463\u2013470. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2017.05.11 (2017).","journal-title":"Chin. J. Cancer Res."},{"key":"22331_CR34","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1158\/1078-0432.CCR-19-3003","volume":"26","author":"L Tang","year":"2020","unstructured":"Tang, L. et al. Characterization of immune dysfunction and identification of prognostic immune-Related risk factors in acute myeloid leukemia. Clin. Cancer Res. 26, 1763\u20131772. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3003 (2020).","journal-title":"Clin. Cancer Res."},{"key":"22331_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-020-0185-8","volume":"8","author":"J Tan","year":"2020","unstructured":"Tan, J. et al. Increased PD-1\u2009+\u2009Tim-3\u2009+\u2009exhausted T cells in bone marrow May influence the clinical outcome of patients with AML. Biomark. Res. 8, 6. https:\/\/doi.org\/10.1186\/s40364-020-0185-8 (2020).","journal-title":"Biomark. Res."},{"key":"22331_CR36","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","volume":"119","author":"LC Ndhlovu","year":"2012","unstructured":"Ndhlovu, L. C. et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119, 3734\u20133743. https:\/\/doi.org\/10.1182\/blood-2011-11-392951 (2012).","journal-title":"Blood"},{"key":"22331_CR37","doi-asserted-by":"publisher","first-page":"1889822","DOI":"10.1080\/2162402X.2021.1889822","volume":"10","author":"J Rakova","year":"2021","unstructured":"Rakova, J. et al. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. Oncoimmunology 10, 1889822. https:\/\/doi.org\/10.1080\/2162402X.2021.1889822 (2021).","journal-title":"Oncoimmunology"},{"key":"22331_CR38","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","volume":"125","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig, C. & Ehninger, G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 125, 3246\u20133252. https:\/\/doi.org\/10.1182\/blood-2014-10-551507 (2015).","journal-title":"Blood"},{"key":"22331_CR39","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/10428190600572673","volume":"47","author":"MJ Greenwood","year":"2006","unstructured":"Greenwood, M. J. et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk. Lymphoma. 47, 1245\u20131252. https:\/\/doi.org\/10.1080\/10428190600572673 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"22331_CR40","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.leukres.2008.01.004","volume":"32","author":"L Marbello","year":"2008","unstructured":"Marbello, L. et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk. Res. 32, 1221\u20131227. https:\/\/doi.org\/10.1016\/j.leukres.2008.01.004 (2008).","journal-title":"Leuk. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22331-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:03:35Z","timestamp":1762549415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22331-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22331"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22331-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of the Peking University People\u2019s Hospital (2020PHB341-01) and was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"38354"}}